L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for BriaCell Therapeutics Corp.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 5:51 pm Purchase | 2022-01-18 | 13G | BriaCell Therapeutics Corp. BCTX | L1 Capital Global Opportunities Master Fund, Ltd. | 4,123 4.200% | 4,123 (New Position) | Filing |
| 2022-02-11 5:47 pm Sale | 2021-12-31 | 13G | BriaCell Therapeutics Corp. BCTX | L1 Capital Global Opportunities Master Fund, Ltd. | 700 11.000% | -5,967 (-89.50%) | Filing |
| 2021-03-05 4:13 pm Purchase | 2021-02-26 | 13G | BriaCell Therapeutics Corp. BCTX | L1 Capital Global Opportunities Master Fund, Ltd. | 6,667 16.300% | 6,667 (New Position) | Filing |